ESSA Pharma Inc. (EPIX)
- Previous Close
5.20 - Open
4.98 - Bid 3.72 x 200
- Ask 5.50 x 300
- Day's Range
4.98 - 5.28 - 52 Week Range
2.58 - 11.67 - Volume
5,035 - Avg. Volume
41,430 - Market Cap (intraday)
232.937M - Beta (5Y Monthly) 1.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.63 - Earnings Date Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
www.essapharma.comRecent News: EPIX
View MorePerformance Overview: EPIX
Trailing total returns as of 8/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EPIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EPIX
View MoreValuation Measures
Market Cap
232.94M
Enterprise Value
102.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.79%
Return on Equity (ttm)
-19.83%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-27.67M
Diluted EPS (ttm)
-0.63
Balance Sheet and Cash Flow
Total Cash (mrq)
130.69M
Total Debt/Equity (mrq)
0.27%
Levered Free Cash Flow (ttm)
-16.1M